ResearcherCasa Sollievo della SofferenzaActive in the last 2 years
Maria Grazia Rodriquenz
Matched on ORCID iD 0000-0002-3163-7982; OpenAlex author ID A5063201200. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 6
- Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
- Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
- Development of a health data derived frailty index as a predictor of adverse outcomes in older patients with pancreatic cancer. Co-author DOI 10.1016/j.jgo.2021.10.009↗
- Assessment of the external validity of the National Comprehensive Cancer Network (NCCN) guidelines for pancreatic ductal adenocarcinoma in a population of olde… Co-author DOI 10.1016/j.jgo.2022.04.015↗
- Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
- Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marina Macchini · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Mariacristina Di Marco · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Giulia Orsi · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Guido Giordano · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Ilario Giovanni Rapposelli · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Monica Niger · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Giampaolo Tortora · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Michèle Milella · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Michele Reni · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Stefano Cascinu · 4 shared papers, 2021–2025 · strength 0.46
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Juan Pablo Negrete‐Najar · 2 shared papers, 2022 · strength 0.40
- Paper Development of a health data derived frailty index as a predictor of adverse outcomes in older patients with pancreatic… DOI 10.1016/j.jgo.2021.10.009↗
- Paper Assessment of the external validity of the National Comprehensive Cancer Network (NCCN) guidelines for pancreatic ducta… DOI 10.1016/j.jgo.2022.04.015↗
- Martine Extermann · 2 shared papers, 2022 · strength 0.40
- Paper Development of a health data derived frailty index as a predictor of adverse outcomes in older patients with pancreatic… DOI 10.1016/j.jgo.2021.10.009↗
- Paper Assessment of the external validity of the National Comprehensive Cancer Network (NCCN) guidelines for pancreatic ducta… DOI 10.1016/j.jgo.2022.04.015↗
- Mario Scartozzi · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Andrea Spallanzani · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Elisa Giommoni · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Alessandro Bittoni · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Silvia Bozzarelli · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Ingrid Garajová · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Lisa Salvatore · 3 shared papers, 2021–2025 · strength 0.37
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. DOI 10.1016/j.esmoop.2020.100032↗
- Umberto Peretti · 3 shared papers, 2021–2023 · strength 0.30
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Paper Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. DOI 10.1016/j.esmoop.2020.100032↗
- Letizia Procaccio · 2 shared papers, 2023–2025 · strength 0.28
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Sara Lonardi · 2 shared papers, 2023–2025 · strength 0.28
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Enrico Vasile · 2 shared papers, 2023–2025 · strength 0.28
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Stefania Mosconi · 2 shared papers, 2021–2025 · strength 0.25
- Paper Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Var… DOI 10.1002/cam4.70364↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
- Anna Maria Militello · 2 shared papers, 2021–2023 · strength 0.21
- Paper Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRC… DOI 10.1038/s41416-022-02086-w↗
- Paper Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic va… DOI 10.1016/j.esmoop.2021.100238↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.